By Suherman Candra Maholtra 
A landmark study scheduled for presentation at the American College of Cardiology’s Annual Scientific Session (ACC.26) has revealed a compelling correlation between the shingles vaccine and a drastic reduction in life-threatening cardiovascular events. According to the research, individuals already diagnosed with heart disease who received a shingles vaccination experienced nearly half the rate of serious heart-related complications within a year of their shot compared to their unvaccinated counterparts. These findings, which draw from a massive repository of clinical data, suggest that the benefits of the shingles vaccine extend far beyond the prevention of a painful skin rash, potentially serving as a critical tool in the management of long-term cardiovascular health.
The study focused specifically on patients with atherosclerotic cardiovascular disease (ASCVD), a condition characterized by the accumulation of plaque—composed of fat, cholesterol, and other substances—within the arterial walls. This buildup narrows the arteries, restricting blood flow and significantly increasing the risk of myocardial infarction (heart attack) and stroke. By examining a high-risk demographic, the research team, led by Robert Nguyen, MD, a resident physician at the University of California, Riverside, sought to determine if the immune-modulating effects of the shingles vaccine could mitigate the inflammatory triggers that often lead to acute cardiac crises.
Methodology and the Use of Real-World Evidence
To reach these conclusions, researchers utilized TriNetX, a sophisticated global health research network that provides access to anonymized electronic medical records from millions of patients across the United States. This platform allowed the team to conduct a retrospective cohort study of 246,822 adults aged 50 and older who were diagnosed with atherosclerotic disease between 2018 and 2025.
The study population was divided into two equal groups of 123,411 individuals. The first group consisted of patients who had received at least one dose of a shingles vaccine—either the recombinant zoster vaccine (Shingrix) or the older live-attenuated vaccine (Zostavax). The second group served as a control, comprising patients with similar health profiles, demographics, and socioeconomic backgrounds who had not been vaccinated against shingles. To ensure the integrity of the comparison, researchers employed propensity score matching, a statistical technique that balances the groups based on variables such as age, gender, race, and the presence of comorbid conditions like hypertension, diabetes, and obesity.
The primary focus of the analysis was the occurrence of major adverse cardiac events (MACE) within a window of one month to one year following vaccination. This timeframe was chosen to isolate the potential protective effects of the vaccine while allowing enough time for the immune system to respond to the inoculation.
Significant Reductions in Mortality and Acute Events
The results of the analysis were strikingly consistent across multiple health metrics. Vaccinated individuals in the high-risk ASCVD category demonstrated a 46% lower likelihood of experiencing a major adverse cardiac event compared to those who remained unvaccinated. Perhaps most notably, the data indicated a 66% reduction in the risk of all-cause mortality during the one-year follow-up period.
Further breakdown of the data revealed specific improvements in several critical areas of heart health:
- Heart Attack Risk: Vaccinated patients saw a 32% reduction in the risk of myocardial infarction.
- Stroke Risk: The likelihood of suffering a stroke decreased by 25%.
- Heart Failure: Instances of new or worsening heart failure were 25% lower in the vaccinated group.
Dr. Nguyen emphasized that the magnitude of these reductions is rarely seen in single-intervention studies. He noted that the protective effect observed is comparable to the cardiovascular benefits gained from major lifestyle changes, such as smoking cessation. The findings suggest that for patients already living with the burden of plaque-filled arteries, the vaccine acts as a secondary layer of defense against the systemic shocks that trigger heart attacks and strokes.
The Biological Link: Inflammation and Clotting
The underlying mechanism behind why a vaccine for a viral skin condition would protect the heart lies in the complex relationship between infection, inflammation, and vascular health. Shingles, or herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nerve tissues near the spinal cord and brain. Years or decades later, the virus can reactivate, often due to age-related declines in immune function.
Medical literature has long established that a shingles outbreak is more than just a localized rash; it is a systemic inflammatory event. During an active shingles infection, the virus can cause significant inflammation in the blood vessels (vasculopathy). This inflammation can lead to the destabilization of existing atherosclerotic plaques. When a plaque ruptures, it triggers the formation of a blood clot, which can then block blood flow to the heart or brain.
Previous studies have shown that the risk of stroke and heart attack spikes significantly in the weeks and months following a shingles diagnosis. By preventing the reactivation of the virus, the vaccine effectively prevents this surge in systemic inflammation. Furthermore, some researchers hypothesize that the vaccine may provide a general boost to the "trained immunity" of the patient, helping the body manage low-level chronic inflammation that contributes to heart disease.
Contextualizing the Findings Within Public Health
The Centers for Disease Control and Prevention (CDC) currently recommends the recombinant shingles vaccine (Shingrix) for adults aged 50 and older, as well as for adults 19 and older who have weakened immune systems. Shingrix is administered in two doses and is more than 90% effective at preventing shingles and its most common complication, postherpetic neuralgia (long-lasting nerve pain).
Despite these recommendations, vaccine uptake remains inconsistent. The study’s authors believe their findings provide a powerful new argument for vaccination, particularly for those hesitant due to "vaccine fatigue" or misinformation. By framing the shingles vaccine not just as a way to avoid a painful rash, but as a preventative measure for heart attacks and strokes, healthcare providers may find more success in encouraging high-risk patients to complete their series.
"Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen stated. "Sometimes patients are unsure about whether they should get a vaccine or not. These results provide another reason for them to elect to get the vaccine."
Chronology of Evidence and Long-Term Outlook
This latest research adds to a growing timeline of evidence suggesting that the shingles vaccine has pleiotropic effects—benefits beyond its original purpose.
- Early 2010s: Retrospective studies began to link shingles outbreaks to a higher immediate risk of stroke.
- 2022-2024: Multiple large-scale analyses suggested that shingles vaccination might be linked to a decreased risk of dementia and Alzheimer’s disease, possibly by reducing neuroinflammation.
- 2025: A study focusing on generally healthy adults found a 23% reduction in cardiovascular events over an eight-year period following shingles vaccination.
- 2026 (The Current Study): The ACC.26 presentation narrows the focus to the highest-risk group (those with existing heart disease), showing even more dramatic short-term benefits (46% reduction in MACE).
While the current study focused on the first year after vaccination, the 2025 data suggests that the cardioprotective benefits could be durable. However, researchers acknowledge certain limitations. One primary concern is the "healthy user bias"—the possibility that individuals who proactively seek out vaccinations are also more likely to follow other healthy behaviors, such as maintaining a balanced diet, exercising, and adhering to heart medications. While the study adjusted for socioeconomic factors, housing stability, and education, it is difficult to entirely eliminate the influence of a health-conscious lifestyle.
Implications for Clinical Practice
The implications of this study are significant for cardiologists and primary care physicians alike. Traditionally, the shingles vaccine has been viewed as a concern for dermatologists or general practitioners. However, if the vaccine is indeed a potent cardioprotective agent, it may soon become a standard recommendation within cardiology clinics.
The potential cost-effectiveness of this intervention is also noteworthy. The financial burden of treating a single heart attack or stroke—including hospitalization, surgery, and long-term rehabilitation—is astronomical compared to the cost of a two-dose vaccine series. From a public health perspective, increasing shingles vaccination rates among the 50+ population could lead to a measurable reduction in healthcare expenditures related to acute cardiovascular crises.
Conclusion and Presentation Details
As the medical community gathers for the ACC.26 Annual Scientific Session, the study titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease" is expected to spark significant discussion. The research underscores a shifting paradigm in preventative medicine: the idea that protecting the body from viral triggers can preserve the integrity of the vascular system.
Dr. Robert Nguyen will present the full findings, including detailed hazard ratios and subgroup analyses, on Monday, March 30, at 12:30 p.m. CT in the Posters section (Hall E). As further research explores the long-term durability of these effects, the shingles vaccine may firmly establish its place not just as a defense against a viral infection, but as a cornerstone of cardiovascular preventative care for the aging population.